Cell proliferation and apoptosis with bcl-2 expression in renal cell carcinoma

Zhang, Xianghua; Takenaka, Ikumasa

doi:10.1016/s0090-4295(00)00645-2

Cited by 27 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This hypothesis was supported by previous findings that showed that Bcl-2 inhibited cell proliferation using bcl-2 trangenic mice (Pierce et al, 2002). Moreover, in the present study, there was a significant positive relation between AI and PI, and the result was consistent with previous findings (Tannapfel et al, 1997;Zhang and Takenaka, 2000).…”

Section: Discussionsupporting

confidence: 94%

“…Indeed, in urothelial transitional cell cancer (Bilim et al, 1998), oesophagus cancer (Hsia et al, 2001) and prostate cancer (Bauer et al, 1996) cases with Bcl-2 positivity represent poor prognosis. However, in RCC, several studies have shown that Bcl-2 positivity was not associated with prognosis (Lipponen et al, 1995;Vasavada et al, 1998;Huang et al, 1999;Sejima and Miyagawa, 1999;Zhang and Takenaka, 2000;Uchida et al, 2002). Unexpectedly, our present study showed that Bcl-2 positivity was associated with better prognosis.…”

Section: Discussioncontrasting

confidence: 53%

“…However, it was unclear whether Bcl-2 positivity was associated with clinicopathological characteristics and prognosis in RCC. Although Bcl-2 expression has also been intensively investigated in other studies, its role in RCC progression and RCC patients prognosis remains controversial (Lipponen et al, 1995;Vasavada et al, 1998;Huang et al, 1999;Sejima and Miyagawa, 1999;Zhang and Takenaka, 2000;Uchida et al, 2002). Results of these studies are summarised in Table 1.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients

et al. 2004

View full text Add to dashboard Cite

Previously, we reported that Bcl-2 was frequently expressed in renal cell carcinoma (RCC) specimens, but p53 mutation was a rare event. However, it was unclear whether Bcl-2 positivity was associated with the clinicopathological characteristics and prognosis in RCC. Therefore, we investigated the expression of Bcl-2 protein and its roles in 101 RCC specimens. In addition, the proliferation index (PI), apoptotic index (AI), caspase-3 and p53 expression were examined. The immunohistochemical method was applied for Bcl-2, caspase-3 and p53 protein expression. To investigate the proliferation activity and apoptosis of tumour cells, PI and AI were calculated based on Ki-67 and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling (TUNEL)-positive cells, respectively. Bcl-2 expression was detected in 72 out of 101 (71.3%) specimens. Bcl-2 positivity was inversely correlated with PI (Po0.0001) and AI (P ¼ 0.0074). Furthermore, Bcl-2 positivity was significantly correlated with better survival (P ¼ 0.0014), and was associated with lower stage (P ¼ 0.0301) and grade (P ¼ 0.0020). In RCC, frequent Bcl-2 expression was correlated with favourable character without higher PI and AI. Thus, Bcl-2 expression might be applied as a novel predictor of better prognosis in RCC patients.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussioncontrasting

confidence: 53%

mentioning

confidence: 99%

See 1 more Smart Citation

Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…High-grade lymphomas such as lymphoblastic lymphoma and Burkitt's lymphoma are characterised by high PI and high AI. A positive correlation between PI and AI has been demonstrated for some types of malignant tumours (Kiberu et al, 1996;Zhang and Takenaka, 2000;Bai et al, 2003). These findings suggest that rapidly proliferating tumour cells may tolerate continuing apoptosis, when there is a high proliferation rate to allow net tumour expansion despite cell loss from apoptosis.…”

Section: Discussionmentioning

confidence: 74%

The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinoma

et al. 2007

View full text Add to dashboard Cite

The Pidd (p53-induced protein with death domain) gene was shown to be induced by the tumour suppressor p53 and to mediate p53-dependent apoptosis in mouse and human cells, through interactions with components of both the mitochondrial and the death receptor signalling pathways. To study the role of Pidd in clinical tumours, we measured its expression by quantitative reverse transcription-PCR in microdissected oral squamous cell carcinomas (OSCC) with and without p53 mutation. Tumour cell apoptosis was assessed by in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling. Tumour proliferation was assessed by immunohistochemical staining for the Ki-67 antigen. We found a wide range of Pidd expression among OSCC. Statistical analysis revealed an association between Pidd expression and apoptotic index (Mann -Whitney test, Po0.001), consistent with a role of Pidd in apoptosis in this tumour type. Furthermore, we showed a positive correlation between apoptotic index and proliferative index that has not been previously described for OSCC. There was no correlation between Pidd expression and the p53 mutation status of these tumours, suggesting that Pidd expression may be regulated by p53-independent mechanisms. Further characterisation of these molecular defects in the control of proliferation and apoptosis should help in developing treatments that target OSCC according to their biological properties.

show abstract

“…Our results are partly in accord with the IHC results from Paraf et al [22] , in which tubulopapillary carcinomas showed strong Bcl-2 immunostaining, whereas only a few Bcl-2-positive cells were observed in clear cell carcinomas. More recently, two studies found no significant correlation of expression among cell types [23,24] . Considering the role of Bcl-2 in anti-apoptotic regulation, it might be expected that Bcl-2 over-expression is correlated with increased cancer cell malignancy.…”

Section: Discussionmentioning

confidence: 97%

Fas Expression in Renal Cell Carcinoma Accurately Predicts Patient Survival after Radical Nephrectomy

Sejima¹,

Morizane²,

Hinata³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Objectives: To investigate Fas, Fas ligand (FasL) and Bcl-2 expression, which are considered to be important apoptotic regulatory factors in renal cell carcinomas (RCCs). Patients and Methods: mRNA quantification and immunohistochemistry allowed for the determination of the expression of these three factors in surgically resected tumors from 82 patients with RCC. The correlation of protein and gene expression with more than 10 years of survival data following nephrectomy (along with clinical and pathologic parameters) was analyzed using uni- and multivariate statistical models. Results: A significantly poorer outcome was observed in patients with tumors expressing high levels of Fas mRNA in the multivariate analysis (p = 0.0002). In addition, patient survival was significantly worse in FasL mRNA-positive tumor cases when compared with FasL mRNA-negative cases (p = 0.0345). Ten cases relapsed more than 5 years after nephrectomy. Among them, the tumors of 8 cases (80%) did not express FasL mRNA. Analysis of Bcl-2 did not show statistical significance of Bcl-2 expression as a prognostic indicator. Conclusions: The data suggest that pronounced Fas expression is a surrogate biomarker of active cancer cell proliferation. Given the FasL tumor counterattack theory, FasL overexpression in RCC may be one of the host immune deficiencies, consequently leading to poor prognosis.

show abstract

Cell proliferation and apoptosis with bcl-2 expression in renal cell carcinoma

Cited by 27 publications

References 28 publications

Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients

Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients

The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinoma

Fas Expression in Renal Cell Carcinoma Accurately Predicts Patient Survival after Radical Nephrectomy

Contact Info

Product

Resources

About